A pivotal gathering focusing on TRML is scheduled for July 21 in New York, organized by Piper Sandler. This event is set to be an important occasion for stakeholders interested in the company's prospects.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for Tourmaline Bio Inc (TRML, Financial) is $55.70 with a high estimate of $70.00 and a low estimate of $35.00. The average target implies an upside of 193.78% from the current price of $18.96. More detailed estimate data can be found on the Tourmaline Bio Inc (TRML) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Tourmaline Bio Inc's (TRML, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.